Details of the Drug

General Information of Drug (ID: DM0GZTD)

Drug Name

L-ornithine phenylacetate

Synonyms

L-ornthine phenylacetate; OCR-002; UCL-L1V; L-ornithine phenylacetate (injectable, acute hepatic encephalopathy); Nitrogen metabolism modulator (injectable, AHE), Ocera; Nitrogen metabolism modulator (injectable, acute hepatic encephalopathy), Ocera; Nitrogen metabolism modulator (injectable, acute hepatic encephalopathy), UCL; Nitrogen metabolism modulator (injectable, hyperammonemia), Ocera; L-ornithine phenylacetate (injectable, AHE), Ocera; L-ornithine phenylacetate (injectable, acute hepatic encephalopathy), Ocera; L-ornithine phenylacetate (injectable, hyperammonemia), Ocera

Indication

Disease Entry	ICD 11	Status	REF
Acute liver failure	DB91	Phase 2	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

268.31

Topological Polar Surface Area

Not Available

Rotatable Bond Count

6

Hydrogen Bond Donor Count

4

Hydrogen Bond Acceptor Count

6

Chemical Identifiers

Formula: C13H20N2O4
IUPAC Name: (2S)-2,5-diaminopentanoic acid;2-phenylacetic acid
Canonical SMILES: C1=CC=C(C=C1)CC(=O)O.C(C[C@@H](C(=O)O)N)CN
InChI: InChI=1S/C8H8O2.C5H12N2O2/c9-8(10)6-7-4-2-1-3-5-7;6-3-1-2-4(7)5(8)9/h1-5H,6H2,(H,9,10);4H,1-3,6-7H2,(H,8,9)/t;4-/m.0/s1
InChIKey: LRSYFEZBIMVWRY-VWMHFEHESA-N

Cross-matching ID

PubChem CID: 44247677
CAS Number: 952154-79-9
TTD ID: D06HFI

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nuclear factor NF-kappa-B (NFKB)	TTSXVID	NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01634230) Emergency Use of OCR-002 in Acute Liver Failure. U.S. National Institutes of Health.
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
4	Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18.
5	Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Auckland Cancer Society Research Centre report
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15.
10	DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91.
11	US patent application no. US20100278784 A1.